JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk

Puja Mehta; Coziana Ciurtin; Marie Scully; Marcel Levi; Rachel C Chambers

doi:10.1183/13993003.01919-2020

JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk

Eur Respir J. 2020 Sep 24;56(3):2001919. doi: 10.1183/13993003.01919-2020. Print 2020 Sep.

Authors

Puja Mehta^{1

2}, Coziana Ciurtin², Marie Scully³, Marcel Levi⁴, Rachel C Chambers⁵

Affiliations

¹ Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, London, UK.
² Dept of Rheumatology, University College London (UCL) Centre for Adolescent Rheumatology, London, UK.
³ Dept of Haematology, University College London Hospital (UCLH), London, UK.
⁴ Dept of Medicine, University College London Hospitals (UCLH), London, UK.
⁵ Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, London, UK r.chambers@ucl.ac.uk.

Abstract

JAK inhibitors have promising therapeutic potential in COVID-19 with dual anti-inflammatory and anti-viral effects. Vigilance to the potentially increased thrombotic risk associated with JAKi is recommended, given the hypercoagulability of COVID-19. https://bit.ly/2NQ15K5

Publication types

Letter
Comment

MeSH terms

Betacoronavirus
COVID-19
Coronavirus Infections*
Humans
Janus Kinase Inhibitors*
Pandemics*
Pneumonia, Viral*
Pulmonary Embolism*
SARS-CoV-2

Substances

Janus Kinase Inhibitors